A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma …
D Heredia, L Mas, AF Cardona, V Oyervides… - Lung Cancer, 2022 - Elsevier
Background Co-occurring genomic alterations identified downstream main oncogenic
drivers have become more evident since the introduction of next-generation sequencing …
drivers have become more evident since the introduction of next-generation sequencing …
Tanshinone IIA reverses gefitinib resistance in EGFR‐mutant lung cancer via inhibition of SREBP1‐mediated lipogenesis
L Zhang, C Xu, J Huang, S Jiang, Z Qin… - Phytotherapy …, 2024 - Wiley Online Library
Abstract Background and Aim Gefitinib resistance is an urgent problem to be solved in the
treatment of non‐small cell lung cancer (NSCLC). Tanshinone IIA (Tan IIA) is one of the …
treatment of non‐small cell lung cancer (NSCLC). Tanshinone IIA (Tan IIA) is one of the …
Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer
Lung cancer (LC) is associated with ageing, with the average age of affected individuals
being approximately 70 years. However, despite a higher incidence and prevalence among …
being approximately 70 years. However, despite a higher incidence and prevalence among …
Based on the development and verification of a risk stratification nomogram: predicting the risk of lung cancer-specific mortality in stage IIIA-N2 unresectable large cell …
Y Yang, C Shen, J Shao, Y Wang, G Wang… - Frontiers in …, 2022 - frontiersin.org
Background The purpose of this study is to predict overall survival (OS) and lung cancer-
specific survival (LCSS) in patients with stage IIIA-N2 unresectable lung squamous cell …
specific survival (LCSS) in patients with stage IIIA-N2 unresectable lung squamous cell …
[HTML][HTML] A randomized phase 2 study of gefitinib with or without pemetrexed as first-line treatment in nonsquamous NSCLC with EGFR mutation: final overall survival …
JCH Yang, Y Cheng, H Murakami, PC Yang… - Journal of Thoracic …, 2020 - Elsevier
Introduction Clinical studies have shown that a combination of a tyrosine kinase inhibitor
(TKI) and pemetrexed overcame acquired resistance to epidermal growth factor receptor …
(TKI) and pemetrexed overcame acquired resistance to epidermal growth factor receptor …
Perdurable PD-1 blockage awakes anti-tumor immunity suppressed by precise chemotherapy
The application of nanocarriers as drug delivery system for chemotherapeutic drugs has
become a research hotspot in cancer treatment. Chemotherapy with high tumor-targeting …
become a research hotspot in cancer treatment. Chemotherapy with high tumor-targeting …
Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice
X Song, L Cao, B Ni, J Wang, X Qin, X Sun… - Frontiers in …, 2023 - frontiersin.org
Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic driver
in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase …
in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase …
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
H Sun, P Ren, Y Chen, L Lan, Z Yan, Y Yang, B Wang… - BMC cancer, 2023 - Springer
Background Non-small cell cancer (NSCLC) patients with concomitant epidermal growth
factor receptor (EGFR) and TP53 mutations have a poor prognosis with the treatment of …
factor receptor (EGFR) and TP53 mutations have a poor prognosis with the treatment of …
[HTML][HTML] Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or …
Y Chen, S Wen, Y Wu, L Shi, X Xu, B Shen - Critical Reviews in Oncology …, 2021 - Elsevier
Objective We conducted a meta-analysis to synthesize the results of published randomized
controlled trials conducted to evaluate the efficacy and safety of epidermal growth factor …
controlled trials conducted to evaluate the efficacy and safety of epidermal growth factor …
[HTML][HTML] Image-guided drug delivery of nanotheranostics for targeted lung cancer therapy
Enormous efforts have been made to integrate various therapeutic interventions into
multifunctional nanoplatforms, resulting in the advance of nanomedicine. Image-guided drug …
multifunctional nanoplatforms, resulting in the advance of nanomedicine. Image-guided drug …